

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO.  
002010-593APPLICATION NO.  
09/915,263INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT

Jing Wu, et al.

FILING DATE

July 27, 2001

GROUP  
1624

MAY 02 2002

C5A

PATENT &amp; TRADEMARK OFFICE

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
B.K.	3,657,341		Thorne, et al. 260/552	4/18/72
	4,410,520		Watthey 424/244	10/18/83
	4,473,575		Watthey 424/263	9/25/84
	5,015,639		Berger et al. 514/213	5/14/91
	5,206,235		Fisher et al. 514/213	4/27/93
	5,247,080		Berger et al. 540/523	9/21/93
	5,486,541		Sterling et al. 514/651	1/23/96
	5,502,048		Chapdelaine et al. 514/413	3/26/96
	5,519,061		Youdim et al. 514/647	5/21/96
	5,532,415		Youdim et al. 564/308	7/2/96
	5,656,626		Chapdelaine et al. 514/213	8/12/97
✓	5,672,598		De et al. 514/212	9/30/97

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
B.K.	EP 0 732 399		Europe	9/18/96		
B.K.	GB 1 519 931		UK	1/6/77		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
B.K.	Semple, et al., "Design, Synthesis and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamides Moieties", <i>J. Med. Chem.</i> , Vol. 39, pp. 4531-4536, (1996).		
Examiner Signature	Burke Kiff	Date Considered	6/6/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.